VHPAR

Xiaojie Chu1, Wei Li1, Margaret G Hines1

  • 1Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States.

Frontiers in oncology
|October 25, 2023
PubMed
概括

针对尿素酶等离子体激活受体 (uPAR) 的两个新型人类VH域抗体显示出对癌症免疫疗法的前景. 这些抗体,当被设计成两种特异性的T细胞参与者时,有效地杀死UPAR阳性癌细胞.